

Appl. No. : 09/762,992
Filed : February 14, 2001

II. Conclusion

The Applicant submits that the above amendments and sequence submission statement and the accompanying sequence listing and computer readable format address the issues raised in the Notification of Missing Requirements under 35 U.S.C. § 371 in the United States Designated/Elected Office (DO/EO/US) mailed February 21, 2002.

The changes made to the specification by the current amendment, including insertions and [deletions], are shown on an attached sheet entitled VERSION WITH MARKINGS TO SHOW CHANGES MADE, which follows the signature page of this amendment. No new matter has been added herewith.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 17, 2002

By: Daniel Hart
Daniel Hart
Registration No. 40,637
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

O:\DOCS\MCM\MCM-1960.DOC
030802

Appl. No. : 09/762,992
Filed : February 14, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification

On page 9, Table 1 and the first paragraph (lines 1-8) have been amended as follows:

Table 1

Cons. B1 CGAAA ACT GTTGA [SEQ ID NO: [7]6]

Cons. B2 TTTCCGAAAGTTGCC [SEQ ID NO: [8]7]

Cons. B3 TCGAAA ACTTTCG [SEQ ID NO: [9]8]

Consensus t **CGAAA** g c c [SEQ ID NO: [10]9]

However, it seems that said consensue nucleotide sequence TXXCGAAAXXGXCXC [SEQ ID NO: [10]9] is not present in other known xylanase nucleotide sequence of other bacteria such as *Bacillus* strains.